• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Lantern Pharma Inc.

    5/21/26 2:44:29 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LTRN alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox not checkedNoneEntity Type
    0001763950
    Lantern Pharma
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Lantern Pharma Inc.
    Jurisdiction of Incorporation/Organization
    TEXAS 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Lantern Pharma Inc.
    Street Address 1Street Address 2
     1920 MCKINNEY AVENUE, 7TH FLOOR
     
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     DALLAS
     TEXAS
     
     75201
     (972) 277-1136 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Sharma
    Panna
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Executive Officer, President



    Last NameFirst NameMiddle Name
    Keyser
    Donald
    Jeffrey
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chairman of the Board



    Last NameFirst NameMiddle Name
    Margrave
    David
    R.
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Financial Officer, Secretary



    Last NameFirst NameMiddle Name
    Bhatia
    Kishor
    G.
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox not checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
    Chief Scientific Officer



    Last NameFirst NameMiddle Name
    Chandru
    Vijay
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Maccecchini
    Maria
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Schalop
    Lee
    T.
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)



    Last NameFirst NameMiddle Name
    Silberstein
    David
    S.
    Street Address 1Street Address 2
     1920 McKinney Avenue, 7th Floor 
     
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75201
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button not checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-05-14
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox not checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox checkedOther (describe)
    private placement of common stock purchase warrants;claiming additional Section 4(a)(2) exemption
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     
     
    (Associated) Broker or DealerCheckbox not checkedNone(Associated) Broker or Dealer CRD Number  Checkbox not checkedNone
     
     
    Street Address 1Street Address 2
     
     
    City State/Province/CountryZIP/Postal Code
     
     
     
    State(s) of Solicitation Checkbox not checkedAll States
     



    13. Offering and Sales Amounts
     
    Total Offering Amount $
    0
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    0
    USD
    Total Remaining to be Sold $
    0
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    The investors paid nothing for the warrants. The warrants were issued as additional consideration for shares of common stock purchased in a concurrent registered offering.
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    6
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    0
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Lantern Pharma Inc./s/ David R. MargraveDavid R. MargraveChief Financial Officer2026-05-21




    Get the next $LTRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LTRN

    DatePrice TargetRatingAnalyst
    3/11/2022$34.00 → $36.00Buy
    HC Wainwright & Co.
    11/2/2021$32.00 → $34.00Buy
    HC Wainwright & Co.
    10/7/2021$32.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $LTRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Silberstein David S.

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    1/13/26 4:05:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously

    3/11/22 6:29:59 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously

    11/2/21 6:34:51 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Lantern Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00

    10/7/21 8:16:17 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    SEC Filings

    View All

    Lantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    6/1/26 7:40:29 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by Lantern Pharma Inc.

    D - Lantern Pharma Inc. (0001763950) (Filer)

    5/21/26 2:44:29 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Lantern Pharma Inc. (0001763950) (Filer)

    5/15/26 4:07:33 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:08 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)

    4 - Lantern Pharma Inc. (0001763950) (Issuer)

    5/14/26 4:10:11 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

    Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. PFS benefit deepens with treatment duration: L858R patients treated through up to six cycles of LP-300 reached an 8.9-month median PFS, versus 8.4 months overall (n=15) – future patients will be eligible to receive up to 8 doses of LP-300. Durable, deep responses: tumor reduction in over 70% of evaluable L858R patients, responses beyond two years, and a 77% clinical benefit rate. Clean, treatment-enabling safety: no clinically meaningful toxicity beyond chemotherapy, comparing favorably with amivantamab plus

    6/2/26 8:13:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

    The FDA raised no objections to Lantern's key proposed protocol amendments to the HARMONIC™ clinical trial. Amendments include: (1) enriching enrollment for patients with EGFR exon 21 L858R mutations; (2) extending LP-300 dosing to a maximum of eight cycles; and (3) transitioning to a single-arm study design — changes that align with emerging data and support a clearer regulatory and partnering path. EGFR exon 21 L858R mutations account for approximately 40% of all EGFR-mutant NSCLC globally and up to 50% in Asian populations — a molecularly defined subset that consistently experiences inferior outcomes when treated with current EGFR-targeted therapies relative to patients with exon

    5/19/26 7:30:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

    Disciplined Execution Drives 47% Reduction in R&D Spend While Advancing Multiple Clinical Programs, Launching Multi-Agentic AI Platform withZeta.ai Commercially, and Strengthening Balance Sheet with Financing of up to $9.25 Million  Q1 net loss reduced 27% year-over-year while progressing multiple precision oncology programs Commercial introduction of withZeta.ai, the first multi-agentic AI co-scientist platform purpose-built for rare and complex cancer drug development Successful outcome from Type C meeting request with the FDA focused on the LP-300 HARMONIC™ Clinical Trial Pediatric brain cancer IND cleared by FDA for enrollment for Lantern Pharma subsidiary, Starlight Therape

    5/15/26 4:01:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Leadership Updates

    Live Leadership Updates

    View All

    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors

    Seasoned Biotech Executive & Wall Street Analyst Brings Deep Expertise in Precision Neurooncology, Biopharma Partnering and Clinical Development Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage biopharmaceutical company using artificial intelligence, machine learning and genomic data to transform the cost, pace and timeline of oncology drug discovery and development, today announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop brings over two decades of combined experience in biotechnology leadership and financial markets, with particular expertise in precision neurooncology and clinical development. Most notably, he co-founded and was a key member

    7/28/25 8:00:00 AM ET
    $CMRX
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives

    DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag

    9/2/21 8:59:00 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Financials

    Live finance-specific insights

    View All

    Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

    Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platforms with multiple clinical stage drug programs, today announced that it will report its first quarter 2026 operating and financial results via press release to be issued on Friday, May 15. The press release will discuss financial results for the first quarter ended March 31, 2026 and provide operational updates on clinical trials and the development of the Company's AI platforms. About Lantern Pharma Lantern Pharma (NASDAQ:LTRN) is a clinical-stage AI-driven precision oncology company trans

    5/11/26 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

    Year of Clinical Validation and Strategic Expansion Across Pipeline, AI Platform Advances Towards Commercialization, and Global Trial Milestones LP-300 Phase 2 HARMONIC™ Trial Progress: Continued enrollment and patient follow-up across the United States, Japan, and Taiwan. Completion of targeted enrollment in Japan across five clinical sites including the National Cancer Center Tokyo. Preliminary data presented at the 66th Annual Meeting of the Japan Lung Cancer Society. Type C meeting package submitted to FDA in March 2026, with meeting scheduled for mid-May 2026 seeking feedback on proposed protocol amendments including focusing enrollment on EGFR exon 21 L858R patients and updating th

    3/30/26 4:05:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET

    Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.  Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2025 operating and financial results webcast on Monday, March 30, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2025 and provide guidan

    3/23/26 4:30:00 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LTRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    3/1/24 4:10:40 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lantern Pharma Inc. (Amendment)

    SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)

    2/14/24 4:05:49 PM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Lantern Pharma Inc. (Amendment)

    SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)

    12/1/23 6:02:25 AM ET
    $LTRN
    Biotechnology: Pharmaceutical Preparations
    Health Care